TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04608331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
Study: NCT05586477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
Study: NCT06604832
Drug: PrabotulinumtoxinA-Xvfs
Normalized name: prabotulinumtoxinA-xvfs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
Study: NCT06610643
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05846646
Drug: IMSA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Study: NCT04610138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water
Study: NCT06050291
Drug: Fixed-Dose Combination (FDC) Tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obicetrapib/Ezetimibe FDC tablet
Study: NCT06153342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05710146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of 100mL of normal saline
Study: NCT04847206
Drug: lysine-3,4-methylenedioxymethamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 171.7 mg lysine-MDMA will be administered.
Study: NCT04847206
Drug: lysine-3,4-methylenedioxyamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A moderate dose of 165.6 mg lysine-MDA will be administered.
Study: NCT04762199
Drug: Flt3/MerTK Inhibitor MRX-2843
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04826159
Drug: IMB-1018972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablet for oral administration
Study: NCT05498766
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
Study: NCT01882296
Drug: AGSPT_10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGSPT 10mg for 7days administration
Study: NCT01882296
Drug: AGSPT_20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGSPT 20mg for 7days administration
Study: NCT01882296
Drug: AGSPT_40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGSPT 20mg x 2tablet for 7days administration
Study: NCT05177640
Drug: 99mTc-Duramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
Study: NCT01013714
Drug: Routine Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
Study: NCT05994131
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally taken once daily
Study: NCT06487624
Drug: HCB301
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCB301 administered via. intravenous (IV) infusion.
Study: NCT06150859
Drug: Ayahausca-Assisted psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions.
Study: NCT05682547
Drug: 0.1% hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study: NCT04646967
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See active comparator description
Study: NCT04646967
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See active comparator description
Study: NCT04646967
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See experimental arm description
Study: NCT06135844
Drug: Purell Hand Sanitizer
Normalized name: ALCOHOL 85 mL in 100 mL TOPICAL SPRAY [PURELL Hand Sanitizer SP Unscented]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient. Ethyl alcohol 70%
Study: NCT03870334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily tablet
Study: NCT04546633
Drug: KAF156
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
Study: NCT04546633
Drug: LUM-SDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
Study: NCT05528172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: NCT02054559
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
Study: NCT05625724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for the control group
Study: NCT06285760
Drug: Standarized diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.
Study: NCT05054803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
Study: NCT04218786
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablet will be given once daily for the span of the study
Study: NCT06612593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive 2 tablets twice daily
Study: NCT06612593
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
Study: NCT04722107
Drug: rAAV2/8-hCYP4V2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
Study: NCT06458413
Drug: Utidelone Capsule Plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle .
Study: NCT04676061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
Study: NCT05486208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC and/or IV.
Study: NCT06336356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once daily.
Study: NCT05794919
Drug: Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g
Approvals — FDA: no, EMA: no, PMDA: no
Description: A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
Study: NCT05794919
Drug: Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
Study: NCT06154304
Drug: Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1
Normalized name: Ventolin HFA 90mcg/actuation Inhalation Aerosol_#1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mcg
Study: NCT06154304
Drug: Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2
Normalized name: Ventolin HFA, 90 mcg/inh inhalation aerosol_#2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg
Study: NCT06154304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06715150
Drug: Azithromcyin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
Study: NCT06729593
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study: NCT05978648
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
Study: NCT04552899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Study: NCT05667662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules with 11.8 mg total powder (excipients only)
Study: NCT06064058
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with NSAIDs and acetaminophen for pain management
Study: NCT05706987
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT05821387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product containing excipients with no active ingredients
Study: NCT04682899
Drug: guideline-guided antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
Study: NCT04511897
Drug: An'ningpai
Approvals — FDA: no, EMA: no, PMDA: no
Description: An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
Study: NCT04682743
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: received intravenous 0.9% normal saline over a 15-minute period.
Study: NCT05262335
Drug: Anlotinib + Oxaliplatin + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study: NCT03813095
Drug: APH-1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
Study: NCT05982106
Drug: TQ05105 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 tablet is a novel JAK2 inhibitor.
Study: NCT05072028
Drug: [14C]DBPR108
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
Study: NCT06194552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered orally
Study: NCT06574568
Drug: YKST02
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT05456724
Drug: TO-O-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
Study: NCT06415019
Drug: Naproxen (BAYH006689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAYH006689 gel will be dispensed directly on the patch
Study: NCT06415019
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel will be dispensed directly on the patch
Study: NCT06415019
Drug: A solution of 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline will be dispensed directly on the patch.
Study: NCT04987112
Drug: CAN1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN1012 IT injection (once every 4 weeks)
Study: NCT04001010
Drug: PPP011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Study: NCT04001010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Study: NCT04865029
Drug: Estradiol Cypionate 5 mg/ml
Normalized name: estradiol cypionate 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
Study: NCT04710719
Drug: Triamcinolone Injection and 5-fluorouracil injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post surgical injection at site of keloid with TAC and 5FU for 3 injections
Study: NCT06234592
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard care vasopressor therapy, norepinephrine infusion
Study: NCT05418465
Drug: Huangqi Guizhi Wuwu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
Study: NCT06240481
Drug: Test Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste \& mouthwash
Study: NCT06240481
Drug: Control Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: toothpaste
Study: NCT05901337
Drug: Convential medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours .
Study: NCT06049576
Drug: Myrciaria dubia Prebiotic Supplement
Normalized name: Myrciaria dubia seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04999761
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
Study: NCT04999761
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
Study: NCT04891302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
Study: NCT06410300
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: checkpoint inhibitor per PI discretion
Study: NCT05930613
Drug: Placebo (NaCl 0.9 % solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
Study: NCT05600686
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05600686
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00000998
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06455761
Drug: 68Ga-FAPI/18F-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study: NCT01315691
Drug: Liposomal amikacin for inhalation
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment.
Study: NCT01315691
Drug: Placebo for liposomal amikacin for inhalation
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days.
Study: NCT06145438
Drug: Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)
Normalized name: Etinilestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug is administered orally at the same time every day
Study: NCT05722262
Drug: K-877-ER
Normalized name: K+ 8 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877-ER tablet
Study: NCT05722262
Drug: CSG452
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSG452 tablet
Study: NCT05013216
Drug: Cohort A: Patients at high risk of developing pancreatic cancer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC
Study: NCT05013216
Drug: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
Study: NCT02451852
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 80mg tablet once daily, open label
Study: NCT06307548
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06307548
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo PDT
Study: NCT06326190
Drug: Local standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.
Study: NCT04864743
Drug: FRSW117
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose.
Study: NCT04927884
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)
Study: NCT04858308
Drug: YYC506
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYC506
Study: NCT04858308
Drug: YYC506 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04858308
Drug: Control Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04553666
Drug: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
Study: NCT06343116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Study: NCT06343116
Drug: Trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
Study: NCT05469126
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.